SCHEMBL43492

SCHEMBL43492

COc1ccc(F)cc1C(C)=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.49
HTT P42858 4/20 0.48
SMN1; SMN2 Q16637 5/20 0.48
LMNA P02545 4/20 0.48
RAB9A P51151 3/20 0.48
NPC1 O15118 1/20 0.48
PKM P14618 1/20 0.48
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
AR P10275 1/20 0.46
CA9 Q16790 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CLK1 P49759 1/20 0.45
CLK2 P49760 1/20 0.45
KDM4E B2RXH2 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6099384 0.86 ALDH1A1 (0.46) HTTSMN1; SMN2LMNARAB9ANPC1
SCHEMBL1020142 0.85 SMN1; SMN2 (0.49) HTTSMN1; SMN2LMNARAB9ANPC1
SCHEMBL30134039 0.85 SMN1; SMN2 (0.49) HTTSMN1; SMN2LMNARAB9ANPC1
SCHEMBL113562 0.85 KEAP1 (0.53) PIN1HTTSMN1; SMN2LMNARAB9A
SCHEMBL29622845 0.85 KEAP1 (0.53) PIN1HTTSMN1; SMN2LMNARAB9A
SCHEMBL16952707 0.84 PIN1 (0.44) PIN1HTTSMN1; SMN2LMNARAB9A
SCHEMBL5756844 0.83 CFD (0.51) HTTSMN1; SMN2LMNARAB9AALDH1A1
SCHEMBL2328719 0.83 PIN1 (0.48) PIN1HTTSMN1; SMN2LMNARAB9A
SCHEMBL4300383 0.83 SMN1; SMN2 (0.52) PIN1HTTSMN1; SMN2LMNARAB9A
SCHEMBL29406733 0.83 PIN1 (0.50) PIN1HTTSMN1; SMN2LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2026-01-29 US disclosed
US-12448611-B2 Transaminase polypeptides CODEXIS, INC. (US) 2025-10-21 US disclosed
US-12378537-B2 Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs CODEXIS, INC. (US) 2025-08-05 US disclosed
US-12305201-B2 Engineered biocatalysts and methods for synthesizing chiral amines CODEXIS, INC. (US) 2025-05-20 US disclosed
WO-2025099238-A1 COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST) Universität Duisburg-Essen (DE) 2025-05-15 WO disclosed
EP-4552639-A1 COMPOUNDS FOR USE IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMOR (GIST) Universität Duisburg-Essen (DE) 2025-05-14 EP disclosed
US-20250101389-A1 BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS CODEXIS INC (US) 2025-03-27 US disclosed
CN-119698468-A Biocatalysts and methods thereof 特沙诺有限公司 2025-03-25 CN disclosed
US-12163162-B2 Biocatalysts and methods for the synthesis of substituted lactams CODEXIS, INC. (US) 2024-12-10 US disclosed
US-20240150732-A1 TRANSAMINASE POLYPEPTIDES INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT 2024-05-09 US disclosed
EP-1075534-B1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2005-05-11 EP disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 WO disclosed
EP-1075534-A4 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 2003-07-09 EP disclosed
EP-1075534-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES Celgro (US) 2001-02-14 EP disclosed
US-6133018-A Enzymatic synthesis of chiral amines using -2-amino propane as amine donor CELGRO (US) 2000-10-17 US disclosed
WO-1999046398-A1 IMPROVEMENTS IN THE ENZYMATIC SYNTHESIS OF CHIRAL AMINES CELGRO (US) 1999-09-16 WO disclosed
EP-0203791-B1 SPIRO-IMIDAZOLIDINES AS ALDOSE REDUCTASE INHIBITORS PFIZER INC. (US) 1989-09-13 EP disclosed
EP-0203791-A1 Spiro-imidazolidines as aldose reductase inhibitors PFIZER INC. (US) 1986-12-03 EP disclosed
US-4575507-A COMPLICATIONS OF DIABETES PFIZER INC. (US) 1986-03-11 US disclosed
US-4251546-A Process for killing internal helminths using certain 1,1-bis-(2-substituted-3-nitrophenyl)alkane or alkylene derivatives ICI AUSTRALIA LIMITED (AU) 1981-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101389-A1 BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS BCAT1, GOT1, OAT PIN1 726/4885HTT 4375/4885SMN1; SMN2 2789/4885
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES GOT1, OAT, PEPD PIN1 568/4885HTT 3072/4885SMN1; SMN2 2464/4885
US-12163162-B2 Biocatalysts and methods for the synthesis of substituted lactams BCAT1, GOT1, OAT PIN1 726/4885HTT 4375/4885SMN1; SMN2 2789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.